glp-1 agonist eli lilly Abu Dhabi, United Arab Emirates – and Company (NYSE: LLY) today reported positive topline results from its Phase 3 ATTAIN-2 trial of orforglipron, an investigational oral receptor agonist, in Eli Lilly and phase results
Pay in 4 interest-free payments of $5.77 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13






:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)




















